Capricor Therapeutics Beheer
Beheer criteriumcontroles 1/4
De CEO Capricor Therapeutics is Linda Marbán, benoemd in Jan2010, heeft een ambtstermijn van 16.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.52M, bestaande uit 8.5% salaris en 91.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.36% van de aandelen van het bedrijf, ter waarde $ 1.41M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.6 jaar en 10.7 jaar.
Belangrijke informatie
Linda Marbán
Algemeen directeur
US$3.5m
Totale compensatie
| Percentage CEO-salaris | 8.52% |
| Dienstverband CEO | 16.6yrs |
| Eigendom CEO | 0.4% |
| Management gemiddelde ambtstermijn | 1.6yrs |
| Gemiddelde ambtstermijn bestuur | 10.7yrs |
Recente managementupdates
Recent updates
Narratiefupdate • Aug 11
CAPR: Post AdCom Regulatory Outcome Will Drive 2026 Upside Potential
Capricor Therapeutics now carries a sharply reduced analyst price target of about $4.38, down from roughly $49.44, as analysts factor in the negative deramiocel AdCom vote, heightened FDA approval concerns, higher perceived risk, and lower projected profitability and P/E multiples. Analyst Commentary Recent research on Capricor Therapeutics has shifted sharply after the deramiocel advisory committee outcome, with most firms now focused on regulatory risk, legal overhangs, and reduced earnings potential.Seeking Alpha • Jul 28
Capricor Therapeutics: Downgrading To Sell As FDA Doubts Mount
Summary Capricor Therapeutics is downgraded to Sell after FDA briefing materials cast doubt on deramiocel’s efficacy in DMD cardiomyopathy. FDA highlighted that HOPE-3’s positive endpoints were only achieved after post-unblinding SAP changes, undermining statistical validity. With deramiocel’s approval in jeopardy and the rest of the pipeline in early stages, CAPR now resembles a preclinical/Phase 1 company. Despite $278.6M cash and no major debt, dilution risk looms as Capricor’s commercial prospects dim and market cap reflects higher uncertainty. Read the full article on Seeking AlphaNarratiefupdate • Jul 27
CAPR: July FDA Panel Vote Will Determine Bullish 2026 Approval Path
Capricor Therapeutics' analyst fair value estimate has been reduced from $54.67 to $49.44, as analysts factor in sharply lower price targets following critical FDA briefing documents on deramiocel, multiple downgrades to Neutral ratings, and increased concern that current data and statistical protocols may not support approval in its present form. Analyst Commentary Recent Street research on Capricor Therapeutics highlights a sharp reassessment of risk around deramiocel ahead of the upcoming FDA advisory committee meeting, with price targets and ratings moving in response to concerns over data integrity, statistical methods, and regulatory pushback.
Nieuw narratief • Jul 12
The Exosome Pioneer: Why Capricor (CAPR) is Poised for an August FDA Breakthrough
Prologue: Witnessing the Exosome Revolution in Clinical Practice As a veterinarian actively running a clinic in 2026, I have seen firsthand the disruptive power of exosome technology. Last year, I introduced an 'exosome ice-needling injection machine' at my hospital to treat some of the most stubborn conditions in small animals.
Narratiefupdate • Jun 15
CAPR: August FDA Decision On Duchenne Therapy Will Drive Long Term Upside Potential
Capricor Therapeutics' analyst price target has been cut by $5, to $38 from $43, as analysts factor in the removal of an expected $80 million milestone payment linked to the NS Pharma dispute and a later modeled U.S. launch for Deramiocel. Analyst Commentary Bullish analysts are recalibrating their models around the NS Pharma dispute and timing of the Deramiocel U.S. launch, yet some still see meaningful potential tied to upcoming regulatory and monetization events.
Narratiefupdate • Jun 01
CAPR: FDA Decision And HOPE-3 Data Will Drive Bullish Repricing
Analysts have trimmed their average price target on Capricor Therapeutics by about $1.60 to roughly $39.40. This reflects adjustments for the removed $80m milestone and a later modeled Deramiocel U.S. launch, while still factoring in upcoming FDA decisions and related catalysts.Narratiefupdate • May 15
CAPR: August PDUFA Decision Will Shape Duchenne Treatment Adoption Outlook
Narrative Update: Capricor Therapeutics Analyst Price Target Shift The analyst price target for Capricor Therapeutics has been reduced by $5 to $38, as analysts factor in the removal of an expected $80 million milestone payment and a later modeled U.S. launch for Deramiocel following the company’s legal action against NS Pharma. Analyst Commentary Recent Street research around Capricor Therapeutics has shifted from purely optimistic toward a more balanced stance, as bullish analysts factor in both regulatory progress for Deramiocel and the impact of the company’s legal action against NS Pharma.Narratiefupdate • Apr 29
CAPR: August PDUFA Cardiac Data Will Drive Bullish 2026 Approval Setup
Narrative Update: Capricor Therapeutics The updated analyst price target framework for Capricor Therapeutics moves from a prior fair value of $50.80 to $54.67. This reflects analysts' use of higher projected revenue growth, wider profit margins and a higher future P/E multiple following recent positive deramiocel data, FDA review progress and a series of target increases across the Street.Narratiefupdate • Apr 15
CAPR: August PDUFA Decision Will Drive Bullish Duchenne Thesis
Analysts have lifted their average price targets on Capricor Therapeutics into a $41 to $63 range, supported by recent FDA progress on deramiocel for Duchenne muscular dystrophy, additional positive Phase 3 HOPE-3 data, and updated cash and review timelines that feed into modest tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions in the valuation model. Analyst Commentary Bullish analysts are largely framing recent volatility in Capricor Therapeutics as a short-term shakeout rather than a shift in the long-term story.Narratiefupdate • Apr 01
CAPR: August PDUFA And HOPE 3 Readout Will Shape Bullish Case
Analysts have lifted their blended price target on Capricor Therapeutics to $63, supported by higher targets from several firms. These firms point to recent FDA milestones for deramiocel in Duchenne muscular dystrophy, additional Phase 3 HOPE-3 data, and updated PDUFA timing as key drivers behind their refreshed assumptions.Narratiefupdate • Mar 18
CAPR: August PDUFA Decision And HOPE 3 Data Will Drive Bullish Outlook
Narrative Update on Capricor Therapeutics The analyst fair value estimate for Capricor Therapeutics has moved from $62.00 to $63.00, reflecting updated Street research that points to higher price targets tied to recent FDA progress for deramiocel in Duchenne muscular dystrophy and supportive Phase 3 HOPE-3 data. Analyst Commentary Recent Street research has been broadly constructive on Capricor Therapeutics, with bullish analysts highlighting regulatory milestones for deramiocel in Duchenne muscular dystrophy and updated Phase 3 HOPE-3 data as key drivers behind their views.Narratiefupdate • Mar 03
CAPR: HOPE 3 Data And BLA Resubmission Will Drive Bullish 2026 Approval Path
Analysts now place a slightly higher implied value on Capricor Therapeutics, with their updated price target moving to $62.00. This is supported by modest tweaks to the discount rate, revenue growth assumptions, and long-term profit margin and P/E inputs.Narratiefupdate • Feb 17
CAPR: HOPE-3 Regulatory Progress And Capital Raise Will Drive Bullish Repricing
Analysts have kept their $41.00 price target for Capricor Therapeutics unchanged, citing only minor model adjustments such as slightly different discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Capricor provided a regulatory update on its Biologics License Application for Deramiocel in Duchenne muscular dystrophy, with the FDA requesting the full Phase 3 HOPE-3 clinical study report and supporting data to address a Complete Response Letter, without asking for additional clinical studies or new patient data.Narratiefupdate • Feb 03
CAPR: Phase 3 Duchenne Cardiac Results Will Shape Bullish 2026 Approval Path
Narrative Update The analyst price target for Capricor Therapeutics has moved from about US$44.56 to US$50.80, with analysts pointing to expectations around Phase 3 HOPE-3 data for Deramiocel in Duchenne muscular dystrophy cardiomyopathy and updated modeling assumptions as key drivers of the change. Analyst Commentary Recent Street research points to a change in how some analysts are framing risk and potential reward around Capricor Therapeutics, especially with Phase 3 HOPE-3 data for Deramiocel in Duchenne muscular dystrophy cardiomyopathy expected in Q4.Narratiefupdate • Jan 20
CAPR: HOPE 3 Cardiac Outcome Data Will Shape Bullish Mid 2026 Approval Path
The analyst price target for Capricor Therapeutics has increased from $12 to $13, as analysts incorporate updated assumptions for Deramiocel approval in Duchenne muscular dystrophy cardiomyopathy and anticipated Phase 3 HOPE-3 cardiac outcome data. Analyst Commentary Bullish analysts are framing the price target move to US$13 as a reflection of updated expectations around Deramiocel in Duchenne muscular dystrophy cardiomyopathy rather than a broad shift in the overall story.Narratiefupdate • Jan 06
CAPR: HOPE-3 Duchenne Cardiac Data Will Drive Bullish Repricing
Analysts have lifted their fair value estimate for Capricor Therapeutics from $12.00 to $41.00 per share, citing updated assumptions around Deramiocel approval prospects in Duchenne muscular dystrophy cardiomyopathy, following recent Street research and price target revisions. Analyst Commentary Recent Street commentary around Capricor Therapeutics has centered on expectations for Deramiocel in Duchenne muscular dystrophy cardiomyopathy, with valuation work closely tied to regulatory outcomes and clinical readouts for the Phase 3 HOPE-3 trial anticipated in Q4.Narratiefupdate • Dec 19
CAPR: Mid 2026 Approval Path Will Drive HOPE 3 Cardiac Catalyst Narrative
Analysts have sharply increased their price target for Capricor Therapeutics, effectively more than doubling fair value from approximately $29 to about $62. They cite higher projected revenue growth, a dramatic improvement in long term profit margins, a more normalized future earnings multiple, and growing confidence that positive HOPE-3 data could support regulatory flexibility and keep a potential Deramiocel approval on track for mid 2026.Narratiefupdate • Dec 05
CAPR: Phase 3 Duchenne Cardiac Data Will Drive 2026 Approval Hopes
Analysts have sharply raised their price target on Capricor Therapeutics, with the modeled fair value estimate climbing from about $20.60 to roughly $44.56 per share. They cite stronger expected revenue growth, significantly improved profit margins, and increasing confidence that positive HOPE-3 Phase 3 data could support Deramiocel approval for Duchenne muscular dystrophy cardiomyopathy on an accelerated mid 2026 timeline.Analyse-artikel • Nov 05
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Analyse-artikel • Sep 09
Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
To the annoyance of some shareholders, Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shares are down a considerable 30...Analyse-artikel • Jun 24
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
To the annoyance of some shareholders, Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shares are down a considerable 25...Analyse-artikel • May 16
Here's Why We Think Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Compensation Looks Fair
Key Insights Capricor Therapeutics to hold its Annual General Meeting on 22nd of May CEO Linda Marbán's total...Analyse-artikel • May 09
Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
Unfortunately for some shareholders, the Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) share price has dived 26% in the...
Nieuw narratief • May 03
FDA Priority Review And NS Pharma Partnership Will Empower Deramiocel
FDA priority review of deramiocel and partnership with NS Pharma could drive significant revenue growth and market penetration.Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$129m |
| Mar 31 2026 | n/a | n/a | -US$115m |
| Dec 31 2025 | US$4m | US$300k | -US$105m |
| Sep 30 2025 | n/a | n/a | -US$82m |
| Jun 30 2025 | n/a | n/a | -US$70m |
| Mar 31 2025 | n/a | n/a | -US$55m |
| Dec 31 2024 | US$2m | US$229k | -US$40m |
| Sep 30 2024 | n/a | n/a | -US$34m |
| Jun 30 2024 | n/a | n/a | -US$28m |
| Mar 31 2024 | n/a | n/a | -US$24m |
| Dec 31 2023 | US$774k | US$221k | -US$22m |
| Sep 30 2023 | n/a | n/a | -US$29m |
| Jun 30 2023 | n/a | n/a | -US$29m |
| Mar 31 2023 | n/a | n/a | -US$29m |
| Dec 31 2022 | US$1m | US$210k | -US$29m |
| Sep 30 2022 | n/a | n/a | -US$27m |
| Jun 30 2022 | n/a | n/a | -US$25m |
| Mar 31 2022 | n/a | n/a | -US$23m |
| Dec 31 2021 | US$2m | US$200k | -US$20m |
| Sep 30 2021 | n/a | n/a | -US$18m |
| Jun 30 2021 | n/a | n/a | -US$18m |
| Mar 31 2021 | n/a | n/a | -US$17m |
| Dec 31 2020 | US$2m | US$150k | -US$14m |
| Sep 30 2020 | n/a | n/a | -US$11m |
| Jun 30 2020 | n/a | n/a | -US$9m |
| Mar 31 2020 | n/a | n/a | -US$7m |
| Dec 31 2019 | US$229k | US$157k | -US$8m |
Compensatie versus markt: De totale vergoeding ($USD 3.52M ) Linda } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.41M ).
Compensatie versus inkomsten: De vergoeding van Linda is gestegen terwijl het bedrijf verliesgevend is.
CEO
Linda Marbán (63 yo)
16.6yrs
Tenure
US$3,521,565
Compensatie
Dr. Linda Marbán, Ph.D. Co-founded Capricor Therapeutics, Inc. (also known as Capricor, Inc). in 2005 and also has been its Chief Executive Officer since 2010 and serves as its President. Dr. Marbán has be...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman of the Board | 14.6yrs | US$735.35k | 0.31% $ 1.2m | |
| Co-Founder | 16.6yrs | US$3.52m | 0.36% $ 1.4m | |
| CFO & Corporate Treasurer | 8.6yrs | US$1.67m | 0.019% $ 74.7k | |
| Executive VP | 14.4yrs | US$1.27m | 0.053% $ 203.2k | |
| Chief Operating & Science Officer | 1.3yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Quality Control | 1.6yrs | geen gegevens | geen gegevens | |
| Chief Development Officer | 1.6yrs | geen gegevens | geen gegevens | |
| Chief Medical Officer | 1.3yrs | geen gegevens | geen gegevens | |
| Chief Commercial Officer | less than a year | geen gegevens | geen gegevens | |
| Director of Biostatistics of Capricor Therapeutics | no data | geen gegevens | geen gegevens | |
| Consultant | no data | geen gegevens | geen gegevens |
1.6yrs
Gemiddelde duur
66.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van CAPR wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.6 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Executive Chairman of the Board | 14.6yrs | US$735.35k | 0.31% $ 1.2m | |
| Co-Founder | 12.8yrs | US$3.52m | 0.36% $ 1.4m | |
| Independent Director | 12.8yrs | US$325.60k | 0.025% $ 95.2k | |
| Independent Director | 12.8yrs | US$380.60k | 0.15% $ 590.8k | |
| Independent Director | 5.1yrs | US$299.97k | 0% $ 0 | |
| Independent Director | 3.1yrs | US$284.34k | 0.0086% $ 33.2k | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | less than a year | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 8.6yrs | geen gegevens | geen gegevens |
10.7yrs
Gemiddelde duur
68yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van CAPR zijn ervaren en ervaren (gemiddelde ambtstermijn van 10.7 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/17 06:14 |
| Aandelenkoers aan het einde van de dag | 2026/08/17 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Capricor Therapeutics, Inc. wordt gevolgd door 10 analisten. 10 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Matthew Venezia | Alliance Global Partners |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Kristen Kluska | Cantor Fitzgerald & Co. |